Laekna Therapeutics

founded in 2016, laekna is a science-driven, clinical-stage biotechnology company committed to bringing novel therapies to cancer, metabolic diseases and liver fibrosis patients worldwide. as of december 31, 2023, we have initiated six clinical trials for afuresertib (lae002), lae001 and lae005 for the treatment of breast cancer, prostate cancer, ovarian cancer and pd-1/ pd-l1 drug-resistant solid tumors to address the unmet medical needs. among these six clinical trials, three are multi-regional clinical trials (mrcts). among the six clinical trials, three are multi-regional clinical trials (mrcts). afuresertib is a potent akt inhibitor that inhibits all three akt isoforms (akt1, akt2 and akt3) as well as one of the only two akt inhibitors in or completed the pivotal-stage clinical development for anti-cancer treatment globally. laekna’s internal drug discovery platform has discovered 14 drug candidates. lae102 is our first internally discovered antibody against actriia. we submitt